转移性肾癌一线治疗药物舒尼替尼、索拉非尼和培唑帕尼的药物经济学评价文献研究(5)
[12] MOTZER RJ，HUTSON TE，TOMCZAK P，et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma[J]. N Engl J Med，2007，356(2)：115-124.
[13] MOTZER RJ，HUTSON TE，TOMCZAKP，et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J]. J Clin Oncol，2009，27(22)：3584-3590.
[14] ESCUDIER B，SZCZYLIK C，HUTSON TE，et al. Randomized phase Ⅱ trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma[J]. J Clin Oncol，2009，27(8)：1280-1289.
[15] ESCUDIER B，EISEN T，STADLER WM，et al. Sorafe- nib for treatment of renal cell carcinoma：final efficacy and safety results of the phase Ⅲ treatment approaches in renal cancer global evaluation trial[J]. J Clin Oncol，2009，27(20)：3312-3318.
[16] MOTZER RJ，HUTSON TE，CELLA D，et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma[J]. N Engl J Med，2014，369(1)：722-731.
[17] LALANI AA，HAOCHENG L，HENG DYC，et al. First- line sunitinib or pazopanib in metastatic renal cell carcinoma：the Canadian experience[J]. Can Urol Assoc J，2017，11(3/4)：112-117.
(收稿日期：2019-10-03 修回日期：2020-01-10)
(編辑：邹丽娟), 百拇医药(刘海娇 吴玉霞 徐伟)
[13] MOTZER RJ，HUTSON TE，TOMCZAKP，et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J]. J Clin Oncol，2009，27(22)：3584-3590.
[14] ESCUDIER B，SZCZYLIK C，HUTSON TE，et al. Randomized phase Ⅱ trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma[J]. J Clin Oncol，2009，27(8)：1280-1289.
[15] ESCUDIER B，EISEN T，STADLER WM，et al. Sorafe- nib for treatment of renal cell carcinoma：final efficacy and safety results of the phase Ⅲ treatment approaches in renal cancer global evaluation trial[J]. J Clin Oncol，2009，27(20)：3312-3318.
[16] MOTZER RJ，HUTSON TE，CELLA D，et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma[J]. N Engl J Med，2014，369(1)：722-731.
[17] LALANI AA，HAOCHENG L，HENG DYC，et al. First- line sunitinib or pazopanib in metastatic renal cell carcinoma：the Canadian experience[J]. Can Urol Assoc J，2017，11(3/4)：112-117.
(收稿日期：2019-10-03 修回日期：2020-01-10)
(編辑：邹丽娟), 百拇医药(刘海娇 吴玉霞 徐伟)